Search
Brentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigational[L1737] Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse … [L1737] The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care.
AMP-101
go.drugbank.com/drugs/DB18253ExperimentalAMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human Dok-7 protein. It is under investigation for the treatment of Dok-7-associated myasthenia.
TP-252
go.drugbank.com/drugs/DB17912ExperimentalTP-252 consists of magnesium L-lysinate bis-eicosapentaenoate, an ionizable salt of eicosapentaenoic acid (EPA), currently being investigated to treat familial adenomatous polyposis.[A259956]
Sulfaguanidine
go.drugbank.com/drugs/DB13726ExperimentalSulfaguanidine is a sulfonamide antibiotic with antimicrobial and antibacterial activities.
Chromium Cr-51
go.drugbank.com/drugs/DB11140ApprovedInvestigationalChromium Cr-51 is an isotope of chromium that has been used as a radioactive label for decades. It is used as a diagnostic radiopharmaceutical agent in nephrology to determine glomerular filtration rate, and in hematology to determine re...
Mixtures: Tricare Prenatal 2-part Daily Prenatal Vitamin SystemMorus alba pollen
go.drugbank.com/drugs/DB10480ApprovedMorus alba pollen is the pollen of the Morus alba plant. Morus alba pollen is mainly used in allergenic testing.
Mixtures: Treatment Set TS333938, Treatment Set TS128872S-8510
go.drugbank.com/drugs/DB06504ExperimentalS-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
Nebicapone
go.drugbank.com/drugs/DB14849Investigationalof Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg). … Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose
Nomifensine
go.drugbank.com/drugs/DB04821ApprovedWithdrawnFDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)). … Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.